-
EP2640381
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2640381
| EP2640381 - CANNABINOID RECEPTOR ANTAGONISTS-INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 16.12.2016 Database last updated on 22.08.2024 | Most recent event Tooltip | 16.12.2016 | Application deemed to be withdrawn | published on 18.01.2017 [2017/03] | Applicant(s) | For all designated states Jenrin Discovery 2515 Lori Lane North Wilimington, Delaware 19810 / US | [2013/39] | Inventor(s) | 01 /
MCELROY, John 2515 Lori Lane North Wilmington Delaware 19810 / US | 02 /
CHORVAT, Robert 1193 Killarney Lane West Chester Pennsylvania 19382 / US | [2013/39] | Representative(s) | Hart, Deborah Mary, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [N/P] |
| Former [2013/39] | Hart, Deborah Mary, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB | Application number, filing date | 11841314.5 | 18.11.2011 | WO2011US61508 | Priority number, date | US20100415051P | 18.11.2010 Original published format: US 415051 P | [2013/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2012068529 | Date: | 24.05.2012 | Language: | EN | [2012/21] | Type: | A2 Application without search report | No.: | EP2640381 | Date: | 25.09.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.05.2012 takes the place of the publication of the European patent application. | [2013/39] | Search report(s) | International search report - published on: | US | 21.11.2013 | (Supplementary) European search report - dispatched on: | EP | 17.04.2014 | Classification | IPC: | A61K9/00, A61K9/20, A61K9/48, C07D231/06, C07D403/10, C07D417/12, C07F9/6503 | [2016/14] | CPC: |
C07D231/06 (EP,US);
A61K9/0019 (EP,US);
A61K9/2018 (EP,US);
A61K9/2059 (EP,US);
A61K9/4866 (EP,US);
A61P1/00 (EP);
A61P1/16 (EP);
A61P29/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
A61P9/12 (EP);
C07D403/10 (EP,US);
C07D417/12 (EP,US);
C07F9/65031 (EP,US)
(-)
|
| Former IPC [2013/39] | A61K31/415, C07D231/06, C07D417/12, A61K31/427, A61P3/04, A61P3/10, A61P3/06, A61P9/00, A61P29/00, A61P1/16, A61P35/00, A61P9/10, A61P9/12, A61P1/00, C07F9/6503, A61K31/683 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/39] | Title | German: | CANNABINOID-REZEPTOR-ANTAGONISTEN/-INVERSAGONISTEN ZUR BEHANDLUNG VON STOFFWECHSELKRANKHEITEN EINSCHLIESSLICH ADIPOSITAS UND DIABETES | [2013/39] | English: | CANNABINOID RECEPTOR ANTAGONISTS-INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | [2013/39] | French: | ANTAGONISTES/AGONISTES INVERSES DU RÉCEPTEUR DES CANNABINOÏDES UTILES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES, Y COMPRIS L'OBÉSITÉ ET LE DIABÈTE | [2013/39] | Entry into regional phase | 18.06.2013 | National basic fee paid | 18.06.2013 | Search fee paid | Examination procedure | 11.12.2013 | Examination requested [2014/04] | 17.11.2014 | Amendment by applicant (claims and/or description) | 08.06.2015 | Despatch of a communication from the examining division (Time limit: M06) | 17.12.2015 | Reply to a communication from the examining division | 17.03.2016 | Communication of intention to grant the patent | 28.07.2016 | Application deemed to be withdrawn, date of legal effect [2017/03] | 02.09.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2017/03] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.06.2015 | Fees paid | Renewal fee | 15.11.2013 | Renewal fee patent year 03 | 16.12.2014 | Renewal fee patent year 04 | 11.11.2015 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.11.2014 | 04 M06 Fee paid on 16.12.2014 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO03026647 (SOLVAY PHARM BV [NL], et al) [Y] 1-11 * example 31 *; | [Y]WO2007125049 (SOLVAY PHARM GMBH [DE], et al) [Y] 1-11 * pages 28,29,36 *; | [Y]WO2007131219 (JENRIN DISCOVERY [US], et al) [Y] 1-11 * paragraph [0022]; examples Tab.2/Expl.3,21,33,62,64,109-114,163-168 *; | [Y]WO2008084057 (SOLVAY PHARM BV [NL], et al) [Y] 1-11* compound 1 * | International search | [Y]US2008255093 (TAM PETER Y [US], et al); | [Y]WO2009059264 (JENRIN DISCOVERY [US], et al); | [Y] - KAPUR, A. ET AL., "Mutation Studies of Ser7.39 and Ser2.60 in the Human CB1 Cannabinoid Receptor: Evidence for a Serine-Induced Bend in CB1 Transmembrane Helix 7", MOL PHARMACOL, (2007), vol. 71, no. 6, pages 1512 - 1524, XP055075518 DOI: http://dx.doi.org/10.1124/mol.107.034645 | by applicant | WO2007131219 | WO2009059264 | - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY, (1990), page 1445 | - BIOCHEM J., (1991), vol. 279, pages 129 - 134 |